iso-fludelone (KOS-1803)
/ Memorial Sloan-Kettering Cancer Center, BMS
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 02, 2023
Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=29 | Completed | Sponsor: Memorial Sloan Kettering Cancer Center | Active, not recruiting ➔ Completed | Trial completion date: Jun 2023 ➔ Jan 2023 | Trial primary completion date: Jun 2023 ➔ Jan 2023
Metastases • Trial completion • Trial completion date • Trial primary completion date • Oncology • Solid Tumor
June 09, 2022
Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=29 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2022 ➔ Jun 2023 | Trial primary completion date: Jun 2022 ➔ Jun 2023
Trial completion date • Trial primary completion date • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1